Maxim Group analyst Jason McCarthy maintained a Buy rating on AIM ImmunoTech (AIM – Research Report) yesterday and set a price target of $3.00. The company’s shares opened today at $0.51.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, NLS Pharmaceutics, and Lineage Therap. According to TipRanks, McCarthy has an average return of -35.0% and a 14.90% success rate on recommended stocks.
Currently, the analyst consensus on AIM ImmunoTech is a Moderate Buy with an average price target of $3.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on AIM ImmunoTech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $21 thousand and a GAAP net loss of $6.39 million. In comparison, last year the company earned a revenue of $33 thousand and had a GAAP net loss of $3.83 million
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AIM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
Read More on AIM:
- AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
- AIM ImmunoTech announces Phase 2 study of Ampligen open, recruiting patients
- AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
- AIM ImmunoTech to participate in event on Long Covid
- Biotech Alert: Searches spiking for these stocks today
